Communities for Immunity Evaluation (Round 2)

Forms and Documents

Document	Type	Status	Availability
IMLS OMB C4I Round 2 Appendices_20220113.docx	Supplementary Document	Uploaded 2022-01-14	Repair queued
IMLS OMB C4I Round 2 Supporting Statement B_20220113.docx	Supporting Statement B	Uploaded 2022-01-14	Repair queued
IMLS OMB C4I Round 2 Supporting Statement A_20220113.docx	Supporting Statement A	Uploaded 2022-01-14	Repair queued

IC Document Collections

IC ID	Collection	Type	Status	Form
249891	Communities for Immunity Evaluation (Round 2)	Instruction	Modified

ICR Details

OMB Control No: 3137-0129	ICR Reference No: 202201-3137-001
Status: Received in OIRA	Previous ICR Reference No: 202110-3137-001
Agency/Subagency: IMLS	Agency Tracking No:
Title: Communities for Immunity Evaluation (Round 2)
Type of Information Collection: Revision of a currently approved collection	Common Form ICR:  No
Type of Review Request: Emergency	Approval Requested By: 01/25/2022
Date Submitted to OIRA: 01/14/2022

	Requested	Previously Approved
Expiration Date	6 Months From Approved	05/31/2022
Responses	1,335	1,188
Time Burden (Hours)	185	120
Cost Burden (Dollars)	7,189	4,688

---

Abstract: The Association of Science and Technology Centers (ASTC) has contracted SRI International (SRI) to conduct an independent evaluation of the Communities for Immunity (C4I) Project. The C4I Project, administered by ASTC in partnership with the American Alliance of Museums (AAM) and the Network of the National Library of Medicine (NLM) and supported by the Institute of Museum and Library Services (IMLS) and the Centers for Disease Control and Prevention (CDC), supports libraries, museums, and their partners to engage local communities with the aim of increasing COVID-19 vaccine confidence and, ultimately, of improving community vaccination rates. The C4I Project also aims to increase libraries’ and museums’ organizational capacity to partner in addressing critical national and local issues. This new emergency clearance request is for the study design and instruments that SRI proposes to use in evaluating C4I Round 2 award activities. Most of the proposed instruments are the same as those used in the Round 1 data collection, which OMB approved on November 15, 2021, under OMB Control Number 3137-0129. In consultation with OMB, IMLS has submitted two separate clearance requests to accommodate two sequential timelines and some variation in approach. Data collection activities for Round 1 activities were scheduled for November through December, 2021, and those for Round 2 activities are scheduled for January through April, 2022. Very brief surveys were appropriate for all Round 1 projects, which had a lower per-project funding ceiling, whereas the higher per-project funding ceiling in Round 2 is likely to result in more in-depth project activities that warrant slightly expanded data collection efforts. This proposed data collection fills an urgent need to understand promising strategies for mitigating vaccine hesitancy and improving vaccination-seeking behavior and vaccination rates in communities around the country. More than 800,000 Americans have died of COVID-19-related causes since February 2020 and, despite widespread availability of the vaccine in the US, only 61 percent of Americans of all ages nationwide are fully vaccinated. In a 2020 survey measuring potential acceptance of a COVID-19 vaccines, just two-thirds (66%) of Americans said that they would definitely or probably get vaccinated when a COVID-19 vaccine became available; subsequent surveys have shown that vaccine hesitancy is a key reason for this choice. Sources of vaccine hesitancy included concerns that fast vaccine approval could reflect lowered quality standards, concerns about the newness of mRNA vaccine development, and misinformation circulated on social media—all despite evidence that vaccines are safe to use. As COVID-19 continues to cause severe illness and death, increasing vaccination rates in the U.S. remains a top national priority. It is also vital to build confidence among parents and caregivers in the recently approved vaccine for children ages 5-11.

Emergency Justfication: The project’s short timeframe reflects the urgency of mitigating COVID-19 impacts, particularly in disproportionately affected communities where the project especially aims to make a difference. IMLS is seeking approval for this collection by January 25, 2022, in order to accelerate the timeline for sharing findings among IMLS stakeholders and with broader national audiences.

---

Authorizing Statute(s): None

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
30-day Notice:	Federal Register Citation:	Citation Date:
	86 FR 57453	10/15/2021
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 1

IC Title	Form No.	Form Name
Communities for Immunity Evaluation (Round 2)

---

ICR Summary of Burden

	Total Request	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	1,335	1,188	0	147	0	0
Annual Time Burden (Hours)	185	120	0	65	0	0
Annual Cost Burden (Dollars)	7,189	4,688	0	2,501	0	0

Burden increases because of Program Change due to Agency Discretion: Yes

Burden Increase Due to: Miscellaneous Actions

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement: Minor change in burden for C4I Round 2.

---

Annual Cost to Federal Government: $32,000

Does this IC contain surveys, censuses, or employ statistical methods? Yes Part B of Supporting Statement

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Yes

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 01/14/2022

---